QualityStocks would like to highlight Aradigm (
OTCBB: ARDM), actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease. The company's team pioneered the AERx® pulmonary delivery platform that was tested in thousands of patients with drugs and biologics including insulin, fentanyl, erythropoietin and nicotine.
In the company’s news,
Aradigm has been awarded a Small Business Initiative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
The $278,000 grant was awarded to assist Aradigm in the investigation of the treatment of pulmonary non-tuberculous mycobacteria (PNTM) infections with the company’s inhaled liposomal ciprofloxacin products, Pulmaquin® and Lipoquin®. The principal investigator is Dr. James D. Blanchard, principal scientist of Preclinical Development at Aradigm. Dr. Luiz Bermudez at the Oregon State University, Corvallis, will lead the laboratory research as a part of the consortium.
“I am very pleased that the National Institutes of Health recognized the potential of our therapeutic approach to become an effective tool to help patients with PNTM infections, a severe chronic respiratory condition that is a growing concern in the U.S. and other countries,” Igor Gonda, president and CEO of Aradigm stated in the press release. “I congratulate Drs. Bermudez and Blanchard on the award that will enable them to leverage the synergies of world class scientists from Oregon State University and Aradigm. We already have a substantial amount of safety information in animal models and humans, as well as efficacy in other infections for Pulmaquin and Lipoquin. This one-year consortium program is an essential prerequisite for entry into advanced human clinical trials in patients with PNTM.”
PNTM infections are a significant and rising cause of morbidity among older adults in the United States. The current clinical paradigm is to treat patients with lung or disseminated disease with combination therapy given orally or intravenously, therapies that Aradigm says often fail.
Pulmaquin has undergone preclinical tests and the ORBIT-2 phase 2b bronchiectasis study, in which outstanding antimicrobial activity and good safety and tolerability were found; the positive impact on prevention of exacerbations compared to placebo was also observed. Aradigm is currently finalizing plans to initiate the phase 3 clinical program in BE with Pulmaquin. Aradigm previously reported positive results in phase 2a studies of Lipoquin.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
